Powder: -20°C for 3 years | In solvent: -80°C for 1 year
TDZD-8 (NP 01139) is an inhibitor of GSK-3β, with an IC50 of 2 μM; minimal inhibitory effect observed on CDK1, casein kinase II, PKA and PKC.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 42.00 | |
10 mg | In stock | $ 53.00 | |
25 mg | In stock | $ 77.00 | |
50 mg | In stock | $ 126.00 | |
100 mg | In stock | $ 198.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 46.00 |
Description | TDZD-8 (NP 01139) is an inhibitor of GSK-3β, with an IC50 of 2 μM; minimal inhibitory effect observed on CDK1, casein kinase II, PKA and PKC. |
Targets&IC50 | GSK-3β:2 μM |
In vitro | TDZD-8 acts as a noncompetitive inhibitor of ATP or GS-1 binding. TDZD-8 shows no inhibition of PKA, PKC, Cdk-1/cyclin B or CK-II in kinase assays. [1] TDZD-8 specifically induces cell death of primary leukemia specimens. TDZD-8 ablates leukemia progenitor and stem cells. TDZD-8 treatment induces oxidative stress. TDZD-8 induces cell death with extremely rapid cell death kinetics showing loss of membrane integrity. TDZD-8 inhibits PKC and FLT3 in primary AML specimens. [2] |
Synonyms | GSK-3β Inhibitor I, NP 01139 |
Molecular Weight | 222.26 |
Formula | C10H10N2O2S |
CAS No. | 327036-89-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: < 1 mg/mL (insoluble or slightly soluble)
DMSO: 44.5 mg/mL (200.21 mM)
Ethanol: 44.5 mg/mL (200.21 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
TDZD-8 327036-89-5 PI3K/Akt/mTOR signaling Stem Cells GSK-3 inhibit GSK-3β Inhibitor I NP-01139 NP01139 Inhibitor TDZD8 GSK-3beta Inhibitor I NP 01139 TDZD 8 GSK-3b Inhibitor I Glycogen synthase kinase 3 Glycogen synthase kinase-3 inhibitor